NCT01392105 - Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Acute Myocardial Infarction

Interventions

DRUG

Mesenchymal stem cell

Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention

DRUG

Control group

No additional treatment of mesenchymal stem cells

Trial Locations (3)

220-701

Yonsei University Wonju College of Medicine, Wonju Christian Hospital, Wŏnju

400-711

Inha University Hospital, Inchon

120-752

Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul

All Listed Sponsors

collaborator

FCB-Pharmicell Co Ltd.

UNKNOWN

lead

Yonsei University

OTHER